专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012062904A3 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER 审中-公开
标题翻译：用于预防和治疗癌症的组合物和方法
公开(公告)号：WO2012062904A3
公开(公告)日：2012-08-30
申请号：PCT/EP2011069931
申请日：2011-11-11
申请人： UTI LIMITED PARTNERSHIP , SANTAMARIA PERE
发明人： SANTAMARIA PERE
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： A61K47/48861 , A61K47/48238 , A61K47/48884 , A61K47/62 , A61K47/6923 , A61K47/6929
摘要： Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cellsto levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells includecytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response againstmetastatic or non- metastaticcancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
摘要翻译：传统的癌症免疫疗法在有效地扩增特异性靶向癌细胞的T细胞方面不足以显着降低体内肿瘤大小或癌细胞数量。为了克服该限制，本文提供了涂布有呈递肿瘤特异性抗原和共刺激分子的MHC I类和/或II类分子的纳米颗粒，以及它们用于扩展当前免疫治疗技术中未达到的抗原特异性抗肿瘤发生T细胞水平。这些抗原特异性抗肿瘤发生T细胞包括细胞毒性T细胞，效应T细胞，记忆T细胞和辅助性T细胞，它们是启动和维持对转移癌或非转移癌，癌前期或肿瘤细胞的实质性免疫应答所必需的体内。本发明描述了靶向循环细胞的癌性或癌前细胞的系统方法，如在淋巴瘤，迁移转移性细胞和实体瘤中。

2. 发明申请

WO2008109852A3 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS 审中-公开
标题翻译：预防和治疗自身免疫病的组合物和方法
公开(公告)号：WO2008109852A3
公开(公告)日：2008-12-11
申请号：PCT/US2008056279
申请日：2008-03-07
申请人： UTI LIMITED PARTNERSHIP , SANTAMARIA PERE , MOORE ANNA
发明人： SANTAMARIA PERE , MOORE ANNA
IPC分类号： A61K39/00 , A61K39/385 , A61P37/00 , A61P37/06
CPC分类号： A61K39/0008 , A61K9/5094 , A61K39/385 , A61K47/6923 , A61K47/6929 , A61K2039/55555 , A61K2039/572 , A61K2039/60 , A61K2039/605 , A61K2039/6093 , A61K2039/627 , G01N33/54313 , G01N33/564 , G01N33/56972 , G01N2333/70539 , G01N2800/042
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：该方法包括根据T细胞的抗原特异性选择性地减少或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，如β细胞特异性T细胞。这样，本发明可用于预防，治疗或改善自身免疫疾病如IDDM。此外，本发明可以用于扩展期望的T细胞，如抗病原性T细胞以预防，治疗和/或改善自身免疫性疾病。

3. 发明申请

WO2005033267A3 ANTIGENS TARGETED BY PREVALENT PATHOGENIC T CELLS IN TYPE 1 DIABETES AND USES THEREOF 审中-公开
标题翻译： 1型糖尿病中预防性致病性T细胞靶向的抗原及其用途
公开(公告)号：WO2005033267A3
公开(公告)日：2005-12-15
申请号：PCT/US2004015752
申请日：2004-05-20
申请人： EINSTEIN COLL MED , DILORENZO TERESA P , EVANS ANNE M , HUNT DONALD F , LIEBERMAN SCOTT M , NATHENSON STANLEY G , SANTAMARIA PERE , SHABANOWITZ JEFFREY
发明人： DILORENZO TERESA P , EVANS ANNE M , HUNT DONALD F , LIEBERMAN SCOTT M , NATHENSON STANLEY G , SANTAMARIA PERE , SHABANOWITZ JEFFREY
IPC分类号： A61K38/04 , A61K39/00 , A61K39/38 , C07K5/00 , C07K14/47 , C07K16/00 , C07K17/00 , C12N20060101 , G01N33/53
CPC分类号： C07K14/4711
摘要： The present invention is based on the identification of a predominant ligand of CD8 T cells that are responsible for type 1 diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several CD8 T cell-binding peptides from IGRP are identified, including the peptide comprising amino acids 206-214 of the IGRP sequence, which has high avidity to the most prevalent T cell receptor of pathogenic CD8 T cells in autoimmune diabetes. The invention thus provides oligopeptide and polypeptide compositions comprising YLKTN/A/I/L/V)FL, FLWSVFWLI, (T/A)YY/G/T)FLNFM, LR(L/V)(F/L)(G/N)IDLL, KWCANPDWI, and SFCKSASIP. Also provided are oligopeptide compositions 8-10 amino acids in length and completely homologous with a mammalian IGRP, where the oligopeptide is capable of binding a human MHC class I molecule. Additionally, various methods of treating a mammal using the above compositions are provided, where the mammal is at risk for or has type 1 diabetes. Also provided are methods of preventing a CD8 T cell that is cytotoxic to pancreatic islet beta-cells from destroying a mammalian beta-cell, where the methods also use the above compositions. Further provided are methods for determining whether a mammal is at risk for or has type 1 diabetes, where the methods use the above compositions.
摘要翻译：本发明基于鉴定负责1型糖尿病的CD8 + T细胞的主要配体。该配体是胰岛特异性葡萄糖-6-磷酸酶催化亚单位相关蛋白（IGRP）。鉴定了来自IGRP的几种CD8 + T细胞结合肽，包括含有IGRP序列的氨基酸206-214的肽，其与自身免疫中病原性CD8 + T细胞最流行的T细胞受体具有高亲合力糖尿病。因此，本发明提供包含YLKTN / A / I / L / V）FL，FLWSVFWLI，（T / A）YY / G / T）FLNFM，LR（L / V）（F / L）（G / N）IDLL，KWCANPDWI和SFCKSASIP。还提供了长度为8-10个氨基酸且与哺乳动物IGRP完全同源的寡肽组合物，其中寡肽能够结合人MHC I类分子。此外，提供使用上述组合物治疗哺乳动物的各种方法，其中哺乳动物处于或具有1型糖尿病的风险。还提供了防止对胰岛β细胞具有细胞毒性的CD8 + T细胞破坏哺乳动物β细胞的方法，其中该方法也使用上述组合物。还提供了用于确定哺乳动物是否处于或患有1型糖尿病的风险的方法，其中所述方法使用上述组合物。

4. 发明申请

WO2005033267A2 ANTIGENS TARGETED BY PREVALENT PATHOGENIC T CELLS IN TYPE 1 DIABETES AND USES THEREOF 审中-公开
标题翻译：预防性1型糖尿病致病T细胞靶向抗原及其应用
公开(公告)号：WO2005033267A2
公开(公告)日：2005-04-14
申请号：PCT/US2004/015752
申请日：2004-05-20
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY , DILORENZO, Teresa, P. , EVANS, Anne, M. , HUNT, Donald, F. , LIEBERMAN, Scott, M. , NATHENSON, Stanley, G. , SANTAMARIA, Pere , SHABANOWITZ, Jeffrey
发明人： DILORENZO, Teresa, P. , EVANS, Anne, M. , HUNT, Donald, F. , LIEBERMAN, Scott, M. , NATHENSON, Stanley, G. , SANTAMARIA, Pere , SHABANOWITZ, Jeffrey
IPC分类号： C12N
CPC分类号： C07K14/4711
摘要： The present invention is based on the identification of a predominant ligand of CD8 + T cells that are responsible for type 1 diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several CD8 + T cell-binding peptides from IGRP are identified, including the peptide comprising amino acids 206-214 of the IGRP sequence, which has high avidity to the most prevalent T cell receptor of pathogenic CD8 + T cells in autoimmune diabetes. The invention thus provides oligopeptide and polypeptide compositions comprising YLKTN/A/I/L/V)FL, FLWSVFWLI, (T/A)YY/G/T)FLNFM, LR(L/V)(F/L)(G/N)IDLL, KWCANPDWI, and SFCKSASIP. Also provided are oligopeptide compositions 8-10 amino acids in length and completely homologous with a mammalian IGRP, where the oligopeptide is capable of binding a human MHC class I molecule. Additionally, various methods of treating a mammal using the above compositions are provided, where the mammal is at risk for or has type 1 diabetes. Also provided are methods of preventing a CD8 + T cell that is cytotoxic to pancreatic islet β-cells from destroying a mammalian β-cell, where the methods also use the above compositions. Further provided are methods for determining whether a mammal is at risk for or has type 1 diabetes, where the methods use the above compositions.
摘要翻译：本发明基于鉴定负责1型糖尿病的CD8 + T细胞的主要配体。该配体是胰岛特异性葡萄糖-6-磷酸酶催化亚基相关蛋白（IGRP）。鉴定了来自IGRP的几种CD8 + T细胞结合肽，包括含有IGRP序列的氨基酸206-214的肽，其对致病性CD8 ^{的最普遍的T细胞受体具有高亲和力 > + T细胞在自身免疫性糖尿病中的作用。本发明因此提供了包含YLKTN / A / I / L / V）FL，FLWSVFWLI，（T / A）YY / G / T）FLNFM，LR（L / V）（F / L） N）IDLL，KWCANPDWI和SFCKSASIP。还提供长度为8-10个氨基酸并与哺乳动物IGRP完全同源的寡肽组合物，其中寡肽能够结合人类MHC I类分子。另外，提供了使用上述组合物治疗哺乳动物的各种方法，其中哺乳动物有患1型糖尿病的风险或具有1型糖尿病。还提供了防止对胰岛β-细胞具有细胞毒性的CD8 + T细胞破坏哺乳动物β-细胞的方法，其中所述方法也使用上述组合物。还提供了用于确定哺乳动物是否有患1型糖尿病或患有1型糖尿病的方法，其中所述方法使用上述组合物。}

5. 发明申请

WO2008109852A2 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS 审中-公开
标题翻译：防止和治疗自身免疫条件的组合物和方法
公开(公告)号：WO2008109852A2
公开(公告)日：2008-09-12
申请号：PCT/US2008/056279
申请日：2008-03-07
申请人： UTI LIMITED PARTNERSHIP , SANTAMARIA, Pere , MOORE, Anna
发明人： SANTAMARIA, Pere , MOORE, Anna
CPC分类号： A61K39/0008 , A61K9/5094 , A61K39/385 , A61K47/6923 , A61K47/6929 , A61K2039/55555 , A61K2039/572 , A61K2039/60 , A61K2039/605 , A61K2039/6093 , A61K2039/627 , G01N33/54313 , G01N33/564 , G01N33/56972 , G01N2333/70539 , G01N2800/042
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括根据T细胞的抗原特异性选择性地还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

6. 发明申请

WO0245735A3 NRP-DERIVED PEPTIDES USEFUL FOR TREATING INSULIN-DEPENDENT DIABETES MELLITUS 审中-公开
标题翻译：用于治疗胰岛素依赖性糖尿病的NRP衍生肽
公开(公告)号：WO0245735A3
公开(公告)日：2003-01-03
申请号：PCT/CA0101744
申请日：2001-12-07
申请人： UNIV TECHNOLOGIES INT , SANTAMARIA PERE
发明人： SANTAMARIA PERE
IPC分类号： A61K38/08 , A61K39/00 , A61P37/02 , C07K7/06 , A61K38/04
CPC分类号： A61K39/0008 , A61K38/08
摘要： This invention relates to NRP-derived peptides ueful for the treatment of autoimmune diseases such as insulin-dependent diabetes melitus (IDDM). The treatment is based on avidity therapy: CD8+ T cells having a high avidity for NRP-derived peptides are deleted, CD8+ T cells bearing a lower avidity are expanded, thus eliminating T cells that are highly toxic to pancreatic beta cells. The principle of avidity therapy could be applied to other autoimmune diseases or cancer.
摘要翻译：本发明涉及用于治疗自身免疫疾病如胰岛素依赖性糖尿病（IDDM）的NRP衍生肽。治疗基于亲和力治疗：缺乏NRP衍生肽具有高亲合力的CD8 + T细胞，具有较低亲合力的CD8 + T细胞扩大，从而消除对胰腺β细胞毒性高的T细胞。亲和力治疗的原则可以应用于其他自身免疫性疾病或癌症。

7. 发明申请

WO2012062904A2 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER 审中-公开
标题翻译：预防和治疗癌症的组合物和方法
公开(公告)号：WO2012062904A2
公开(公告)日：2012-05-18
申请号：PCT/EP2011/069931
申请日：2011-11-11
申请人： UTI LIMITED PARTNERSHIP , SANTAMARIA, Pere
发明人： SANTAMARIA, Pere
IPC分类号： A61K47/48
CPC分类号： A61K47/48861 , A61K47/48238 , A61K47/48884 , A61K47/62 , A61K47/6923 , A61K47/6929
摘要： Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cellsto levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells includecytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response againstmetastatic or non- metastaticcancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
摘要翻译：常规的癌症免疫治疗不足以有效扩展特异性靶向癌细胞的T细胞，其数量足以显着降低体内肿瘤大小或癌细胞数量。为了克服这个限制，本文提供的纳米颗粒涂覆有呈现肿瘤特异性抗原和共刺激分子的MHC I类和/或II类分子及其在目前免疫治疗技术中未达到的扩增抗原特异性抗致瘤性T细胞水平的用途。这些抗原特异性抗致瘤性T细胞包括毒性T细胞，效应T细胞，记忆T细胞和辅助T细胞，其是启动和维持针对转移性或非转移性癌，癌前或肿瘤细胞的实质性免疫应答所必需的体内。本发明描述了靶向癌细胞或前癌细胞的系统方法，其是循环细胞，如在淋巴瘤，迁移性转移细胞和实体瘤中。

8. 发明申请

WO2008109852A8 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS 审中-公开
标题翻译：防止和治疗自身免疫条件的组合物和方法
公开(公告)号：WO2008109852A8
公开(公告)日：2009-08-06
申请号：PCT/US2008056279
申请日：2008-03-07
申请人： UTI LIMITED PARTNERSHIP , SANTAMARIA PERE , MOORE ANNA
发明人： SANTAMARIA PERE , MOORE ANNA
IPC分类号： A61K39/00 , A61K39/385 , A61P37/00 , A61P37/06
CPC分类号： A61K39/0008 , A61K9/5094 , A61K39/385 , A61K47/6923 , A61K47/6929 , A61K2039/55555 , A61K2039/572 , A61K2039/60 , A61K2039/605 , A61K2039/6093 , A61K2039/627 , G01N33/54313 , G01N33/564 , G01N33/56972 , G01N2333/70539 , G01N2800/042
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括根据T细胞的抗原特异性选择性地还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式